As we begin to close a record year for biotech IPOs, three more biotechs have jumped on the Nasdaq, each raising more than 20 million more than their initial targets.
Seer, Sigilon Therapeutics and Silverback Therapies grew by 17 175 million, 6 126 million and 1 241.5 million, respectively, adding to the total pot of અ 13 billion this year.
Sere priced its 9.8 million shares at પ 1 ap, which is in the range of $ 16 to 18 18 earlier this week. Redwood City, CA-based biotech is initially set to raise million 150 million. It was started by CEO Omid Farooqzad, who left his piece in the nano-drug lab at Brigham and Women’s Hospital in Boston to create a company around technology that he said would change the field of protomics.
Continue reading Endpoints with a free subscription
Unlock this story right away and join End 94,600+ Biopharma Profs every day reading EndPoints – and it’s free.
